華信新材(300717.SZ)業績快報:2019年淨利潤升10.83%至5173.94萬元
格隆匯2月21日丨華信新材(300717.SZ)披露2019年度業績快報,報告期內,公司實現營業收入3.16億元,同比增長2.97%;營業利潤5668.30萬元,同比增長3.80%;利潤總額5971.12萬元,同比增長9.39%;歸屬於上市公司股東的淨利潤5173.94萬元,同比增長10.83%;基本每股收益0.51元。
營業總收入及營業利潤較上年同期增長的主要原因是公司主營業務收入同比增加,產品結構進一步優化,其中PC系列產品、彩色卡基系列產品、非接觸卡基材料等中高端系列產品銷售收入同比增加。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.